Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Paul Oberstein, MD
Phone
(212) 305-0592
Email
po2178@columbia.edu

Dr. Paul Oberstein received his medical degree from the Ohio State University College of Medicine. He completed residency training in Internal Medicine at Temple University Hospital and fellowship training in Hematology/Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center. He also completed a Masters in Biostatistics in Patient-Oriented Research at the Mailman School of Public Health. Dr. Oberstein specializes in the care of patients with GI malignancies with an emphasis on interdisciplinary collaboration with surgical, GI, and radiation oncology partners.

Dr. Oberstein is a principal investigator of over 10 ongoing clinical trials, evaluating novel therapeutic approaches as well as palliative and supportive care interventions for patients with GI malignancies. Dr. Oberstein is conducting research to elucidate the complex interplay between tumor associated stroma and epithelial cancer cells utilizing mouse models of pancreatic cancer in collaboration with the Olive Lab in the Herbert Irving Comprehensive Cancer Center. The goal of this research is to develop greater understanding of the mechanism of chemoresistance and conduct pre-clinical tests of novel therapeutics in order to expand treatment options for patients with advanced cancer. His work has been presented at national conferences and recognized with a Young Investigator Award from the American Society of Clinical Oncology and a KL2 Mentored Career Development Award.


Clinical Studies Managed By Dr. Oberstein:
More InfoTitleSponsorIRB Number
Details[CLOSED] A Study for patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma using study drug pembrolizumabMerckAAAO8259
DetailsA study for patients with gastric cancer using study drug PembrolizumabMerck Sharp & Dohme Corp.AAAQ9871
DetailsA study for patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors using study drug RO6958688Hoffmann-La RocheAAAR2410